About the company
Crescendo Biologics is a private, clinical stage immuno-oncology company developing novel, targeted T cell enhancing Humabody® therapeutics based on a unique, patent protected, discovery platform.
Leading its proprietary pipeline, Crescendo has developed CB307, a novel half-life extended CD137 x PSMA Humabody. CB307 is designed to achieve a longer lasting anti-cancer effect whilst avoiding systemic toxicity, and the clinical programme for CB307 is underway in patients with PSMA positive solid tumours (NCT04839991).
![](https://eu-admin.eventscloud.com/file_uploads/35bd915c28dcca47441ebcb5f12f4487_profile-pic1.png)
Theodora Harold
CEO
Crescendo Biologics are looking to connect with:
Pharmaceutical Companies; Biotechnology Companies; Investors; Clinical Trial Investigators.
Interested in connecting with Crescendo Biologics?
Submit enquiry![](https://eu-admin.eventscloud.com/file_uploads/0410d8f35ea402e39861faa65cc1dbfc_crescendo-biologics.jpg)
Crescendo Biologics are looking to connect with:
Pharmaceutical Companies; Biotechnology Companies; Investors; Clinical Trial Investigators.
Id voluptate laborum quibusdam repudiandae debitis quam. Consequatur voluptas dicta sapiente eos magnam aut. At non dignissimos facere unde suscipit quis molestias.Accreditation